Loading
A phase 1/2 trial of Ivonescimab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, now recruiting.
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07623356 by Akeso, with 265 participants planned, started 2026-07-07 and due to reach its primary completion in 2028-06-18. Interventions recorded: AK138D1, Ivonescimab, Carboplatin. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Akeso, Ivonescimab, Bispecific antibodies, Small-cell lung cancer.
Shares Akeso, Ivonescimab, Bispecific antibodies, Small-cell lung cancer.
Shares Akeso, Ivonescimab, Bispecific antibodies, Carboplatin.
Shares Akeso, Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Akeso, Ivonescimab, Carboplatin, Small-cell lung cancer.
Shares Akeso, Ivonescimab, Bispecific antibodies, Carboplatin.
Shares Akeso, Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Akeso, Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors.